Navigation Links
Evista Not A Cure For Heart Disease

Evista is the market name of the drug raloxifene HCl is manufactured by drug maker Eli Lilly & Co. a study was conducted which showed that Evista// , a drug used to treat osteoporosis in women, did not prevent heart attacks. The study analyzed 10,000 women in 26 countries for a period of seven years. It was studied whether if this drug given daily for the study period would lower the risks of heart attack and breast cancer in postmenopausal women who either had heart disease or were at high risk for heart attack.

Raloxifene HCl is mainly used to treat and prevent osteoporosis in postmenopausal women. But since this study proved that the drug did not prevent heart attacks the company wanted to reinforce for physicians that Evista should not be prescribed for cardioprotection. Lilly Chief Medical Officer Alan Breier said in a statement that they have gathered new data on Evista's potential to reduce the risk of invasive breast cancer in postmenopausal women. It plans to submit the details of its study to the Food and Drug Administration for review. But further analysis would be needed and precautionary measures to be taken before announcing the use of the drug with respect to breast cancer.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Evista Not Cure For Heart Disease

(Date:8/28/2008)...conventional therapy, study found , , TH... a treadmill improves brain function and fitness f...ugh the usual rehabilitation program, a new study ...ts have," said study researcher Dr. Andreas Luft, ...itation at the University of Zurich in Switzerland...
(Date:8/28/2008)...al efforts of the Maryland Medicaid contract, HAR...ional medical,management firm, appointed Lenaye La...or. Dr. Lawyer will oversee all clinical aspects o...unt Valley, Maryland Harrisburg,office., "Dr. Law...yland," said,Alice Stollenwerk Petrulis, MD, FACP,...
(Date:8/28/2008)...d physical, especially for the impaired, study say... -- A new study says that 13 percent of American s...buse. , The University of Chicago researchers ..., being taken advantage of financially (3.5 percen...o found that seniors with physical impairments wer...
(Date:8/28/2008)...ding dermatology company serves growing profession... Palo Alto, CA (PRWEB) August 28, 2008 -...l firm, today announced that together with Mustang...ding a Series A round of financing for Profex.Inc....vested $15.5 million in the round. Profex, a leadi...
Breaking Medicine News(10 mins):Health News:Treadmill Workouts Help Stroke Survivors 2Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:13% of Seniors Report Being Mistreated 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3
...ricans and others are not taking enough vitamin D,...developing cancer, according to a landmark study c...e. The four-year, randomized study followed 1,17... rural eastern Nebraska.* Participants taking calc...
...-like reactions to newer iodine-containing contras...ildren according to a recent study conducted by r... Center and C.S. Mott Childrens Hospital both in A..., risk associated with iodine-containing contrast ...
...n is used to treat a variety of tumors and the res...helial cell death, which in turn limits oxygen d...ll death. Recently, radiation-induced hypoxia was ...a the activation of new blood vessel formation (an...
...er of those hit by the debilitating Alzheimers acr...gest jump is projected for Asia. At the moment th...atients, at 12.6 million. By 2050, the region wi...orld's 106 million Alzheimer's, researchers at Joh...
Other Medicine News:Health News:Vitamin D Reduces Cancer Risk 2Health News:Newer Contrast Agents Safe for Children 2Health News:Alzheimers Incidence is Set to Quadruple by 2050 2
(Date:8/28/2008)..., Austria, Aug. 28 /- Intercell AG (V...rck & Co., Inc. has initiated a Phase II,clinical ...prevention of,Staphylococcus aureus (S. aureus) in...ntrolled study aims to evaluate the safety and imm...ith end-stage kidney disease on,hemodialysis. This...
(Date:8/27/2008)...ing Research Team Makes Crucial Breakthrough in Ba...inson,s Disease, CHICAGO, Aug. 27 /-...y announced that scientists at The University of N...battle to slow or prevent the onset,of a very comm... researchers have genetically produced the first e...
(Date:8/26/2008)...mpany to present data from landmark SYNTAX clinica...Call/ -- Boston Scientific,Corporation (NYSE: BSX...ajor,events and press announcements at the Europea...from August 30 to September 3 in Munich, Germany.,... the SYNTAX trial,which compares percutaneous cor...
(Date:8/26/2008)..., Mass., Aug. 26 /- Cambridge Researc...ase of the Maestro(TM) EX In,Vivo Imaging System. ...,FLEX technology and becomes the entry-level instr... (Photo: http://www.newscom.com/cgi-bin/prnh/200...gnificant advancement of CRi,s unique,solid-state ...
Breaking Medicine Technology:Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 2Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 3The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price 2BioMed Realty Trust Announces Exercise of Over Allotment Option for Common Stock 4777 1BioMed Realty Trust Announces Exercise of Over Allotment Option for Common Stock 4777 2BioMed Realty Trust Announces Exercise of Over Allotment Option for Common Stock 4777 3Gene Variant Boosts Risk for Stress Related Ischemia 17446 1Gene Variant Boosts Risk for Stress Related Ischemia 17446 2OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival 17442 1OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival 17442 2Prostate cancer screening program leads to bigger fall in death rates than surrounding areas 17438 1Prostate cancer screening program leads to bigger fall in death rates than surrounding areas 17438 2Prostate cancer screening program leads to bigger fall in death rates than surrounding areas 17438 3
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens.
...nd probe system used together to quantify gene exp... system is a sandwich nucleic acid hybridization a...tion and quantification, by amplifying the reporte...nched DNA allows immediate quantification of targe...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits.
Clearview Simplify D-dimer test kits
Medicine Products: